559397
SB 202190
InSolution, ≥98%, p38 MAP kinase inhibitor
别名:
InSolution SB 202190, InSolution p38 MAP Kinase Inhibitor II
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H14FN3O
化学文摘社编号:
分子量:
331.34
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
产品名称
SB 202190, InSolution, ≥98%, p38 MAP kinase inhibitor
SMILES string
Fc1ccc(cc1)C2=C(NC(=C4C=CC(=O)C=C4)N2)c3ccncc3
InChI
1S/C20H14FN3O/c21-16-5-1-13(2-6-16)18-19(14-9-11-22-12-10-14)24-20(23-18)15-3-7-17(25)8-4-15/h1-12,23-24H
InChI key
NJNKPVPFGLGHPA-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
liquid
potency
16 nM IC50
16 nM Ki
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
protect from light
shipped in
wet ice
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
Cell permeable: yes
Primary Target
P38β
P38β
Product competes with ATP.
Reversible: yes
Target Ki: 350 nM against the kinase activity of p38β; 280 nM against p38 phosphorylation of activating transcription factor 2 (ATF-2)
Disclaimer
Toxicity: Irritant (B)
General description
A potent and cell-permeable inhibitor of p38 MAP kinase. Inhibits p38 phosphorylation of myelin basic protein (MBP) with no effect on the activity of the ERK or JNK MAP kinase subgroups. Also inhibits the kinase activity of p38β (IC50 = 350 nM) and p38 phosphorylation of activating transcription factor 2 (ATF-2; IC50 = 280 nM). Blocks LPS-induced TNF-α and interleukin biosynthesis. Reported to block LDL expression in Hep52 cells.
Other Notes
Ajizian, S.J., et al. 1999. J. Infect. Dis.179, 939.
Singh, R.P., et al. 1999. J. Biol. Chem.274, 19593.
Wang, S.W., et al. 1999. Inflamm. Res.48, 533.
Gallagher, T.F., et al. 1997. Bioorg. Med. Chem.5, 49.
Jiang, Y., et al. 1996. J. Biol. Chem.271, 17920.
Kramer, R.M., et al. 1996. J. Biol. Chem.271, 27723.
Li, Z., et al. 1996. Biochem. Biophys. Res. Commun.228, 334.
Lee, L.C., et al. 1994. Nature372, 739.
Singh, R.P., et al. 1999. J. Biol. Chem.274, 19593.
Wang, S.W., et al. 1999. Inflamm. Res.48, 533.
Gallagher, T.F., et al. 1997. Bioorg. Med. Chem.5, 49.
Jiang, Y., et al. 1996. J. Biol. Chem.271, 17920.
Kramer, R.M., et al. 1996. J. Biol. Chem.271, 27723.
Li, Z., et al. 1996. Biochem. Biophys. Res. Commun.228, 334.
Lee, L.C., et al. 1994. Nature372, 739.
Packaging
Packaged under inert gas
Please refer to vial label for lot-specific concentration.
Physical form
A 1 mg/ml solution of SB 202190 (Cat. No. 559388) in anhydrous DMSO.
Preparation Note
Following initial thaw, aliquot and freeze (-20°C).
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
10 - Combustible liquids
wgk
WGK 1
flash_point_f
188.6 °F - closed cup - (Dimethylsulfoxide)
flash_point_c
87 °C - closed cup - (Dimethylsulfoxide)
Xiao Cui et al.
Cell biology international, 44(9), 1811-1819 (2020-05-07)
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system that is caused by the interaction of genetic and environmental factors. Current studies have shown that Fc-receptor like-3 (FCRL3) is closely related to MS, but the specific role
Matriptase drives dissemination of ovarian cancer spheroids by a PAR-2/PI3K/Akt/MMP9 signaling axis.
Nisha R Pawar et al.
The Journal of cell biology, 222(11) (2023-09-22)
The transmembrane serine protease matriptase is a key regulator of both barrier-disruptive and protective epithelial cell-cell interactions. Elevated matriptase is a consistent feature of epithelial ovarian cancers (OvCa), where multicellular spheroids shed from the primary tumor into the peritoneal cavity
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持